Laboratory Studies Sample Clauses

Laboratory Studies. Completion of all physician ordered laboratory studies, related to the patient’s specific chronic condition, within the timelines of recommended national guidelines.
AutoNDA by SimpleDocs
Laboratory Studies. Because the establishment of Longfin Smelt in culture is still in development, the opportunity to study these behaviors in a lab setting has only recently become available. These efforts can be useful for understanding behaviors of several life stages. • Telemetry methods for adults: Telemetry technology has been improving over time and may be at a point where its applicable for use on Longfin Smelt adults. This approach can provide greater resolution in movement patterns up and down the SFE by older fish and perhaps hatchery surrogates, once available via improved culture methods. • Modeling studies: Use of 3D particle tracking models to test different swimming behaviors for young fish, and comparisons with observed fish distributions. Additional Considerations Many of the methods described above would require permitting for collection and sampling of wild fish. The number of permits required may depend on the location of sampling. If sampling were to occur in the Delta, then permits for take would be needed under both ESA and CESA due to geographic overlap with Delta smelt and other federally listed fish species. Laboratory studies are currently limited because Longfin Smelt culture is in early stages of development and wild broodstock is limited. However, it is expected that Longfin Smelt culture practices will continue to improve over time and minimize this limitation in the future. SPAWNING AND REARING HABITATS FOR LONGFIN SMELT ‌ Introduction Like Delta Smelt, spawning and rearing habitats for Longfin Smelt remain poorly understood. Identification of these core habitats will improve habitat restoration actions aimed at benefiting the species. Characterizing and mapping spawning and rearing habitat throughout the Delta are also important for understanding potential impacts as a result of operations of the SWP. For these reasons, spawning habitat was identified as an area of scientific priority within the ITP and a core component of this Priority Area within the LFSSP. Connection to Condition of Approval 7.6.3: Longfin Smelt Science Priorities Work conducted within this priority area is expected to inform the following priorities identified in Condition of Approval 7.6.3 of the ITP: • Characterize Longfin Smelt spawning substrate and spawning microhabitat requirements. • Improve understanding of Longfin Smelt spawning substrate distribution in the Delta, Cache Slough, and Suisun Xxxxx Key Background Information Longfin Smelt have been described as seme...
Laboratory Studies. Because the establishment of Longfin Smelt in culture is still in development, the opportunity to study these behaviors in a lab setting has only recently become available. These efforts can be useful for understanding rearing behavior and preferences. Additional Considerations Longfin Smelt spawning runs can be rapid, occur overnight during the winter with inclement weather in habitats that are difficult to access. As a result, there are considerable logistical challenges associated with identifying exact spawning locations. Additionally, methods to identify eggs may need to be developed. Some of the methods described above would require permitting for collection and sampling of wild fish. The number of permits required may depend on the location of sampling. If sampling were to occur in the Delta, permits for take would be need for both the state and federal endangered species acts due to overlap and potential take of Delta smelt or other federally listed fish species. This sampling would need to be coordinated through IEP to ensure proper permit and take coverage. Laboratory studies are currently limited because Longfin Smelt culture is in early stages of development and wild brood stock is limited. However, it is expected that Longfin Smelt culture practices will continue to improve over time and minimize this limitation in the future. LITERATURE CITED Xxxxx, X., Xxxxxx, X. and Xxxxxx, M.S., 2007. Genetic effects of captive breeding cause a rapid, cumulative fitness decline in the wild. Science, 318(5847), pp.100-103. Xxxxx, X. and Xxxxxx, C., 2010. Is hatchery stocking a help or harm? Evidence, limitations and future directions in ecological and genetic surveys. Aquaculture, 308, pp.S2-S11. Xxxxxx, X.X., Xxxxxx, X.X., Xxx Xxxxxx, X.X., Xxxxxx, X., Xxxxxx, X.X., Xxxxxxxx, X., Xxxxxx, X.X., Xxxxxx, X.X. and Xxxxxxxxxxx, L.B., 2016. Multi-generational evaluation of genetic diversity and parentage in captive southern pygmy perch (Nannoperca australis). Conservation genetics, 17(6), pp.1469-1473. Xxxxxxxx M.R., A.M. Goodbla, X.X. Xxxxxxxxx, X.X. Xxxxxxxxxx, O.O. Xxxxxxxxx, X. Xxxxx, and A.D. Xxxxxxxx (2020) Rapid and accurate species identification for ecological studies and monitoring using CRISPR-based SHERLOCK. Molecular Ecology Resources 20(4): 961-970. Xxxxxxxxxxx, X. and Xxxxxxxx, C., 2004. The effect of light intensity, alga concentration, and prey density on the feeding behavior of delta smelt larvae. In American Fisheries Society Symposium (Vol. 3...

Related to Laboratory Studies

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Trials The Ship shall run the following test and trials:

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

Time is Money Join Law Insider Premium to draft better contracts faster.